Japanese guidelines for atopic dermatitis 2020

Allergol Int. 2020 Jul;69(3):356-369. doi: 10.1016/j.alit.2020.02.006. Epub 2020 Apr 4.


Atopic dermatitis (AD) is a disease characterized by relapsing eczema with pruritus as a primary lesion, which is frequently encountered in clinical practice. Skin barrier dysfunction leads to enhanced skin irritability to non-specific stimuli and epicutaneous sensitization. In the lesion site, a further inflammation-related reduction in skin barrier function, enhanced irritability and scratching-related stimuli deteriorate eczema, leading to vicious cycle of inflammation. The current strategies to treat AD in Japan from the perspective of evidence-based medicine consist of three primary measures: (i) the use of topical corticosteroids and tacrolimus ointment as the main treatment for the inflammation; (ii) topical application of emollients to treat the cutaneous barrier dysfunction; and (iii) avoidance of apparent exacerbating factors, psychological counseling and advice about daily life. The guidelines present recommendations to review clinical research articles, evaluate the balance between the advantages and disadvantages of medical activities, and optimize medical activity-related patient outcomes with respect to several important points requiring decision-making in clinical practice.

Keywords: Atopic dermatitis; Clinical practice guidelines; Eczema; Evidence-based medicine; Treatment.

Publication types

  • Practice Guideline
  • Review

MeSH terms

  • Clinical Decision-Making
  • Dermatitis, Atopic / diagnosis*
  • Dermatitis, Atopic / etiology
  • Dermatitis, Atopic / therapy*
  • Disease Management
  • Disease Susceptibility
  • Humans
  • Japan